(Q36521866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Everolimus: an immunosuppressive agent in transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Jignesh K Patel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

1347-1355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Lung transplants with tacrolimus and mycophenolate mofetil: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Sirolimus therapy in cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Oral everolimus inhibits in-stent neointimal growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Review of the proliferation inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report--2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1347

10.1517/14656566.7.10.1347

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805720%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference